Immunization Registries in Latin America and the Caribbean


M. Carolina Danovaro, MD, MSc Comprehensive Family Immunization Unit *March*, 2014





Vaccination Cards CERTIFICADO DE VACUNACION FECHA DE APLICACION PRIMERA SEGUNDA TERCERA PERUERZO ... ANTISARAMPION BCG22 MAR LUM XXXXX XXXXX XXXXX XXXXX BLOQUEO ANTIPOLIO 18/3/05 XXXXX XXXXX XXXXX XXXXX XXXXXCCIN! 5R = 24 min ex or Cog Hoce MINISTÈRE DE LA SANTÉ PUBLIQUE ET DE LA POPULATION - HAITI TRIMO VAX 22-1-84 **MWEN RESEVWA** 2ème DÒZ VAKSEN POLYO UNX PARTY MANUFACTURE 3: 21-5-84 19-8-94 10-6-95


Tally sheets or equivalent



Individual Records



Example of an individual vaccination record – then entered into a computerized registry







What is a National Electronic Immunization Registry (EIR)?

- Immunization registries: Electronic information system, confidential, population-based, with identification data sent directly from vaccination providers (Linkins et al, 2001 y Freeman et al. 2003).
 - Not to be confused with immunization information systems
- Population-based information system, confidential, with vaccination data (doses given) from an entire country
 - it had outputs to facilitate coverage monitoring by vaccine, dose, geographical area, age and provider
 - It supports individual (and timely) schedule follow-up





NATIONAL Public Sector EPI DEPARTAMENT/ Social Security **REGION** Immunization Registry **Electronic DISTRICT Private Sector HEALTH CENTER** Other providers





Advantages of Electronic Immunization Registries

- Coverage monitoring by cohort ("dynamic denominator) instead of using an annual goal
 - Coverage may vary depending on time report is run
 - More precise coverage may facilitate vaccine and supply forecasting
- Allows for a detailed analysis of who is un/under vaccinated to tailor vaccination strategies
- Individual follow-up of persons with delayed vaccines
 - No more negative drop-out rates
 - It may facilitate timely vaccination
- If well designed and implemented can be easy to use and well accepted






Characteristics of an Ideal Immunization Registry for Latin America

- Inclusion of all persons at birth, or as early as possible
- Unique ID
 - National ID or birth registration ID
 - Unique combination: names, parental names or their ID, birth date/place
 - Biometrics: fingerprints, iris
- Information about each person, including info on geographical area of residence
- Information about the vaccines given, dates, and provider
- Allowing aggregation of data by geographical level, as required
- Allowing timely individualized follow-up
- Data entry as close to vaccination as possible (time and place)
- Data security and protection of patient confidentiality





Electronic Immunization Registries in Latin America and the Caribbean, 2013




Various Approaches

- Relation to national Health Information System (HIS)
- Development and maintenance
- Relation to other immunization systems
- Financing
- Software
- Data entry (usually from paper)
- Data flow
 - Web-based
 - "Disconnected version"





2000s: API* and other systems



Large quantities of data but incompatible database systems








How to solve this problem?

▶2009: NIP and the Department of the Ministry of Health Informatics developed a new information system, combining all of the old systems into one.




Unifying the database systems

Source: MOH Brazil






Practical Uses of an Immunization Registry





EPI ON THE WEB, DATABASE FOR TRACKING BIRTH COHORT

2011	COHORTE			2012										
2011	COHORIE	Marzo	Abril	Mayo	Junio	Julio	Agosto	eptiembr	Octubre	loviembr	Diciembre	Enero	Febrero	Marzo
Enero	6294	5232	857	103	33	16	9	6	2	2		2	4	6
Febrero	5557		4564	778	97	38	17	7	7	3	2		2	2
Marzo	6324			5023	1042	112	45	25	6	5	2	1	1	4
Abril	5940				4688	992	125	28	18	8	7	5	1	
Mayo	6239					4837	1033	128	30	6	7	5	4	2
Junio	6008						4929	745	75	35	15	9	4	11
Julio	6159							4930	846	103	35	27	7	6
Agosto	6469								5039	1086	102	48	19	13
Septiembre	6632									5310	924	143	49	24
Octubre	6003										4585	1089	124	40
Noviembre	5768											4838	704	100
Diciembre	5775												4526	1107
TOTAL	73168	2947	3114	3366	3173	3200	3293	3106	3201	3493	3091	6176	5445	1315



Source: Health Secretariat Bogota











EPI ON THE WEB, GETTING A VACCINATION CARD







Contents lists available at SciVerse ScienceDirect

Vaccine





Review

Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: An evaluation using existing data

Teresa Picón^a, Lucía Alonso^b, Gabriela García Gabarrot^c, Noelia Speranza^a, Mariana Casas^d, Fernando Arrieta^e, Teresa Camou^c, Raquel Rosa^b, Lucia Helena De Oliveira^f, Jennifer Rabke Verani^{g,*}

ARTICLE INFO

Article history: Received 17 August 2012 Received in revised form 7 November 2012 Accepted 30 January 2013

Keywords: Streptococcus pneumoniae Pneumococcal infections Pneumococcal vaccines Uruguay

ABSTRACT

The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine immunization program in Uruguay in March 2008 with a 2-dose primary series (given at 2 and 4 months) plus a booster (at 12 months) and a catch-up campaign (two doses given at 15 and 17 months). We used a case-control methodology and existing laboratory surveillance and immunization registry data from Uruguay to evaluate PCV7 effectiveness against vaccine-type invasive pneumococcal disease (VT-IPD). Cases of VT-IPD (with pneumococcus obtained from a normally sterile site) were identified through the National Reference Laboratory. Age- and neighborhood-matched controls were obtained through a national immunization registry in which all children are enrolled at birth regardless of vaccine receipt; all eligible controls were included. Immunization status of cases and controls was assessed through the immunization registry, and conditional logistic regression was used to calculate PCV7 effectiveness. Between April 2008 and February 2010, 44 cases of VT-IPD among children < 5 years were identified; 43 (98%) of those children were located in the registry. Among located case patients, 7 (16.3%) were ageeligible to have received at least one dose of PCV7. A total of 637 matched controls were included. Vaccine effectiveness was 91.3% (95% CI: 46.4, 98.6) for >1 PCV7 doses and 94.8% (95% CI: 43.1, 99.5) for >2 PCV7 doses. Using existing data we demonstrated high effectiveness of PCV7 against VT-IPD in Uruguay-a middle-income country using a 2-dose primary series plus a booster dose and a limited catch-up campaign. These data also highlight the utility of surveillance and high-quality immunization registries for evaluating the effectiveness of vaccines.

ganización Indial de la Salud Iméricas

Published by Elsevier Ltd.

² Immunization Unit, Epidemiology Division, Ministry of Public Health, Montevideo, Uruguay

b Epidemiology Division, Ministry of Public Health, Montevideo, Uruguay

⁶ National Reference Laboratory, Ministry of Public Health, Montevideo, Uruguay


^a Surveillance Department, Epidemiology Division, Ministry of Public Health, Montevideo, Uruguay

^{*}Immunization Department, Honorary Commission for the Fight Against Tuberculosis and other Prevalent Diseases, Montevideo, Uruguay

Pan American Health Organization, Washington, DC, USA

E Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, USA


Linking mHealth to EIRs







Source: MOH Guatemala



Access to Data

1. Web application



2. Mobile application





Tal ID 57 1245
Add Insu CM - Ephonoly 1
Participal D
First name
Gender
Date of Birth
Place of Birth
Ever Velg Coron

3. Paper flow



Slide by Jan Grevendonk, PATH






Innovations

Mobile Data Entry Clerk: An Innovative Idea Worth Exploring

n the context of project Optimize, 1,2 the Minstry of Public Health and Social Welfare of Juatemala proposed and developed guideines for the use of mobile data entry clerks. Each clerk would be responsible for visiting

ion of a municipal health authority and the Americas.

closest health facility with access to Inter- electronic data system and in those where net. Each clerk would be required to possess having computers and Internet in each health a valid driver's license, maintain up-to-date post may not be feasible. However, possible antivirus software on his or her computer risks include accidents, robberies, and loss equipment, and sign in and sign out all equip- of data. A program using mobile data entry Clerks would work under the direct su- clerks has yet to be evaluated in the field in



Recommended Immunization Schedule for Persons Aged 0 Through 6 Years—United States • 201

For those who fall behind or start late, see the catch-up schedule

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19-23 months	2-3 years	4-6 years	
Hepatitis B ¹	HepB	НерВ				He	рВ					
Rotavirus ²			RV RV		RV2						Salahan	Range of
Diphtheria, Tetanus, Pertussis ³			DTaP	DTaP	DTaP	aP see Donote ³		TaP			DTaP	ages for all
Haemophilus influenzae type b ⁴			Hib	Hib	Hib4	Hib						children excep certain high-ris
Pneumococcal ⁶			PCV	PCV	PCV	PCV				PF	SV	groups
Inactivated Poliovirus ⁶			IPV	IPV		IPV					IPV	
Influenza ⁷								uenza (Ye	arly)			Range of recommended
Measles, Mumps, Rubella ⁸						MMR		see footnot		tnote ⁸ MMR		ages for certai high-risk group
Varicella ⁹						Varicella			see footnote ⁹		Varicella	
Hepatitis A ¹⁰							HepA (2 doses)		HepA	Series	
Meningococcal ¹¹										M	CV	

This schedule includes recommendations in effect as of December 15, 2009. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Considerations should include provider assessment, patient preference, and the potential for adverse events. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendation http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant advers events that follow immunization should be reported to the Vaccine Adverse Ever Reporting System (VAERS) at http://www.vaers.hhs.gov or by telephon-



Potential Problems with Admin Coverage and with Immunization Registries

Administrative (aggregated data)

- Errors (voluntarily and involuntary) recording vaccine doses
- Errors in aggregating data
- Errors in data entry
- Inaccurate denominators
- Not including doses given by the private sectors or other providers

Immunization Registry

- Errors (voluntarily and involuntary) recording vaccine doses
- Errors in data entry
- Incomplete registry or duplicates
- Not including doses given by the private sectors or other providers






Lesson Learned – EIRs take time

	2007	2009	2010	2011	2012
	Análisis, modelamiento y diseño del sistema.	Construcción del aplicativo WEB.	■ Pruebas, ajustes TRES (3) módulos priorizados ■ WEB.	■Pruebas, ajustes al WEB.	■Pruebas, ajustes a incidencias en marcha WEB.
w		3 meses(Oct-dic)	■ Capacitación	■ Capacitación	Mejoramiento en la infraestructura
E B		Sin pruebas		Inicio Implementación acompañada en Neiva.	■Fortalecimiento talento humano.
B					Implementación en 1493 de 2732* puntos a implementar.
D E S C O N E		-	 Definición y construcción del Desconectado TRES (3) módulos priorizados 	Pruebas y ajustes al Desconectado.	■Mejoras al Desconectado.
T A D					

Source: MOH Colombia

Lesson Learned – IT Developments have cycle: Skipping a step may affects quality and/or costs and/or time,




Source:PHII

Lesson Learned – EIR implementation must be closely monitored

BECRETARIA DE SALUD DE HONDURAS MONITOREO DEL PILOTO DEL SINOVA ENTRUCIÓN: MECHA: / / / / / / / / / / / / / / / / / / /							\neg	•	Pro	C	es	S										
								•	Da	ta	qu	ıal	ity	•								
IVO DE LA SUP Verificar congru SINOVA Base de	uenda de la	información ent	re la información de	el VAC-2 <5 años	vs formulario	SINOVA-1	ıs	•	Pro	b	ler	ns	fa	CE	d	by	u u	se	rs			
Verificar la calic	dad de la Info	rmación ingresa	da al SINOVA.				ENERU 2	1112					FEBRERU	1 2012					MARZU	2012		
			uar la fundionalidad			CONGRUE	NCIA		CALIDAD		COL	IGRUEN			CALIDAI	D	C	ONGRUEN		T	CALIDA	.D
Generar compre	omisos de ac.	ierdo a los halla	umano sobre el mar ezgos encontrados.		TOTAL BO TAC-2 HEBSBA 8	TOTAL DOSI	S INDICADOR B	TOTAL EGISTROS ETISADOS 56		30	TOTAL DOSIS						HERREAL FAC-S TOTAL BOSIS	TOTAL BOSIS	*DIV/0!	REGISTROS RETISADOS	TOTAL	* DIV
GRUENCIA EN aluado:	ITRE LA INFO	ORMACION SO	BRE DOSIS APLIC	A																		圭
Goupe de Stad	Siclésice sca tjes, 5- AN	A VAC-2	S SINOVA-1	C SINOVA-base de detos	(Si/ No)		CALIDAD DE % de Registri si 100-199 re	os a re gistros	visar depen	00-399 r	registros; 1				egistros	en el mes	; 20%					
	Sector 1							ATOS PE	RSONALES		UBICACIÓ	N GEOGRA		0	OSIS APUIC	ADAS						
	Sabin 1						Variab		Total de regisi on errores e s date		Variable	con one	e registros res o sin el lato	Variab		Total do registres co errores	-					
41 min	Note 1						Usolded			de	enciacione • osciociones			Sessore <	elik.							
	Nauma 1					-	Nactive			Ů.	unidein de einiene			1 - 4 etca			_					
	Septe 2 Sebin 2						Secous				endamente Geologia			CARCACAGE CARCACAGE Salk)	(от,							
							Section (ie la			uniciais de autonia			With the P	`							
							Gouss Go	iss		9	validet de eutooia											
											Marca.											

Mundial de la Salud

OFICINA REGIONAL PARA LAS Américas



Open Research Questions

- Impact of EIR on program performance in different settings
- Usefulness of data for performance monitoring
- Feasibility of implementation and maintenance
 - How to make sure that systems become institutionalized in the health system and are sustainable





Registry Data for Research

While more research is needed, registries can also produce the data that is required for effective research into:

- Vaccine effectiveness
- Vaccine hesitancy
- Vaccine safety
- Equity
- Program efficiency





Acknowledgments

- Countries of the Americas
 In particular, immunization programs
- PAHO: Immunization, Health Analysis and Statistics and KMC
- WHO
- Partners (CIDA, CDC, BMGF, UNICEF, GAVI, TEPHINET, IMeCA, Optimize)









